GX BIO LABS · Product artwork
Tesamorelin is a growth hormone-releasing hormone analogue studied in defined clinical populations, particularly people with HIV-associated abdominal fat accumulation. Published findings concern the study formulations and do not establish the properties of this research vial.
Not currently available
Check COA availabilityCOA not yet available for this strength
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
Tesamorelin research examines the relationship between growth hormone signalling, abdominal adipose tissue and liver fat. A randomised study in adults with HIV and abdominal fat accumulation measured visceral and hepatic fat alongside metabolic outcomes. A later multicentre trial focused on people with HIV and non-alcoholic fatty liver disease, using liver fat and histology assessments. These are studies in selected clinical populations, with specific formulations and monitoring. They provide context for endocrine research, but cannot be extended to general weight management, healthy volunteers or the identity, purity and performance of a separately supplied research material.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
A placebo-controlled study in adults with HIV-associated abdominal fat accumulation measured visceral and liver fat. It reported reductions in these study endpoints; the authors described the work as preliminary and noted uncertainty about long-term clinical importance.
Read studyA multicentre trial examined liver fat and histology in people with HIV and non-alcoholic fatty liver disease. Liver fat decreased relative to placebo; further work was needed on long-term histological outcomes.
Read studyTesamorelin is currently listed in 5 mg, 10 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
No laboratory report is currently published for this compound. Request the available documentation before relying on any batch-specific measurement. A scientific paper is not a substitute for a COA.
A catalogue listing is not a laboratory measurement. Check original documentation for the selected strength and batch before relying on identity, purity or quantity information.
Ipamorelin is a synthetic peptide studied as a growth hormone secretagogue and ghrelin-receptor agonist. Its literature includes animal pharmacology and a human trial of postoperative bowel function, with distinct endpoints and limitations.
This listing is CJC-1295 No DAC. The linked human study concerns the related, long-acting albumin-binding CJC-1295 compound and is provided as context, not direct evidence for the no-DAC material.
HGH denotes human growth hormone. Clinical research on recombinant growth hormone formulations, including somatropin, provides endocrine context but does not validate the identity, potency or clinical suitability of a research vial.